Interim report from DIAGNODE-1 shows continued positive clinical course
Diamyd Medical today announced that a sixth interim report from the investigator initiated DIAGNODE-1 trial, an open label clinical pilot trial in which the diabetes vaccine Diamyd® is given directly into the lymph node, shows a continued positive clinical course in terms the patients’ own ability to produce insulin as well as long-term blood sugar and insulin dose when nine patients have been followed for 15 months.In a sixth interim report from the open label investigator initiated clinical pilot trial DIAGNODE-1, where the diabetes vaccine Diamyd® is administered directly into the lymph
